Peplin joins list of developers to drop IPO

You can count Peplin on the growing roster of developers that couldn't make a go of an IPO. The Emeryville, CA-based company cited "unfavorable market conditions" as its reason for dropping the IPO, which was filed with the SEC last year. A string of biotechs have made a similar move as investors have proved difficult to win over at a time public markets are badly roiled. Peplin had planned to use the IPO money to fund development of dermatology therapies. The company has a special focus on treating skin cancers. Shares of Peplin trade on the Australian exchange.

- read the AP story

Suggested Articles

AstraZeneca is picking up a delayed preclinical fibrosis candidate from RedX in a deal that gives the U.K. biotech a much needed cash boost.

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.